WRAL Tech Wire

Raleigh firm BDSI targets growing drug abuse, addiction markets

BioDelivery Sciences plans to file a new drug application for its opioid dependence treatment BEMA Buprenorphine in the first half of 2013.

How BDSI technology works

FDA concerns lead to delay in BDSI cancer drug relaunch

Over Onsolis' two-year shelf life, the product's pink appearance can fade. The FDA told the Raleigh company that the color change could confuse patients and the agency is directing BDSI to make formulation changes.

BioDelivery Sciences makes clean sweep in patent fight

The U.S. Patent and Trademark Office has rejected all claims made by MonoSol Rx in the third MonoSol patent that the New Jersey company alleged BDSI had infringed. In total, MonoSol had made 222 claims covering three of its patents.

Triangle news: Bandwidth.com; BioDelivery Sciences; SAS; Precision BioSciences; Novella Clinical; SlickEdit

Bandwidth.com division Inetwork expands management team; BDSI says it prevails in patent fight; SAS makes knowledge management firm list; Precision files patent suit; Noval Clinical division adds new exec; SlickEdit to tout software to gamers.

Raleigh-based BioDelivery Sciences prevails in patent fight

Specialty pharmaceutical company BDSI says the USPTO has rejected all of the claims asserted by rival MonoSol in the latest patent claim. Both companies have technologies that deliver drugs via a small piece of film that dissolves in the mouth.

How BDSI technology works

Raleigh-based BDSI secures patent, $15M payment

BioDelivery Sciences' patent for its drug delivery technology triggers a milestone payment from its partner Endo Pharmaceuticals.

Raleigh-based BioDelivery Sciences gears to raise $40M

The Raleigh-based specialty pharmaceutical company has filed a shelf registration that would allow BDSI to raise up to $40 million by selling stock if it needs the money.

BioDelivery Sciences strikes license deal worth up to $180M

The Raleigh-based company receives an upfront payment of $30 million from Endo Pharmaceuticals for rights to its treatment technology for chronic pain.

BDSI

FDA changes should benefit BioDelivery Sciences

Some opioid painkillers used by cancer patients are governed by U.S. Food and Drug Administration plans to manage possible health risks. The FDA is changing how it manages these drugs and these changes should help BDSI.

BDSI

BioDelivery Sciences scores victory in patent dispute

The US Patent and Trademark Office has rejected all 191 claims made by New Jersey-based MonoSol Rx as unpatentable. The dispute centers on the technology that forms BDSI's drug delivery platform.

BioDelivery Sciences runs short on cash, time

The company has $15.1 million in cash. But the Raleigh-based firm is working on two clinical-stage drug programs and it doesn't have enough money to pay for both of them.

Raleigh drug firm BDSI takes aim at $1B opioid drug market

"We believe we are on course to become one of the first products to compete with Suboxone, a product with sales in excess of a billion dollars annually and currently without competition," CEO Mark Sirgo says.

BioDelivery Sciences not phased by drug's trial failure

The Raleigh-based company also says potential partners are still interested in the pain reliver.

BioDelivery Sciences drug candidate fails in trial

The chronic pain reliver didn't perform better than a placebo in a Phase 3 clinical trial, but the Raleigh company isn'r giving up.

BioDelivery Sciences prepares for launch of pain killer in Canada

The Raleigh-based drug firm gears to sell breakthrough cancer pain reliver after working through production problems.